Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart FailureThe purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
40 to 90
Participation Criteria
Inclusion Criteria
- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Exclusion Criteria
* Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Study Location
Hamilton General Hospital
Hamilton General HospitalHamilton, Ontario
Canada
Contact Study Team
Catherine Demers, Site 0007
Local Institution - 0011
Local Institution - 0011Montreal, Quebec
Canada
Contact Study Team
Local Institution - 0040
Local Institution - 0040Toronto, Ontario
Canada
Contact Study Team
Local Institution - 0035
Local Institution - 0035Trois-Rivieres, Quebec
Canada
Contact Study Team
Local Institution - 0037
Local Institution - 0037Toronto, Ontario
Canada
Contact Study Team
Local Institution - 0030
Local Institution - 0030Toronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Bristol-Myers Squibb
- Participants Required
- More Information
- Study ID:
NCT06122779